セリン/スレオニンプロテインキナーゼPim3(Pim3がん遺伝子)の世界市場2022

◆英語タイトル:Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Global Markets Directが発行した調査報告書(GMDHC22022TDB)◆商品コード:GMDHC22022TDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2022年3月
◆ページ数:46
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥518,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥1,036,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD10,500 ⇒換算¥1,554,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本調査レポートでは、開発中のセリン/スレオニンプロテインキナーゼPim3(Pim3がん遺伝子)市場について調査・分析し、セリン/スレオニンプロテインキナーゼPim3(Pim3がん遺伝子)概要、治療薬開発、開発段階別の開発中製品、治療領域別の開発中製品、疾患別の開発中製品、企業別の開発中製品、大学/機関別の開発中製品、治療薬分析、作用機序別分析、投与経路別分析、分子タイプ別分析、治療薬開発に携わる企業など、以下の項目を掲載しております。
・セリン/スレオニンプロテインキナーゼPim3(Pim3がん遺伝子)-概要
・セリン/スレオニンプロテインキナーゼPim3(Pim3がん遺伝子)-治療薬開発
・開発段階別の開発中製品
・治療領域別の開発中製品
・疾患別の開発中製品
・企業別の開発中製品
・大学/機関別の開発中製品
・セリン/スレオニンプロテインキナーゼPim3(Pim3がん遺伝子)-治療薬分析
・作用機序別分析
・投与経路別分析
・分子タイプ別分析
・セリン/スレオニンプロテインキナーゼPim3(Pim3がん遺伝子)-治療薬開発に携わる企業

Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) – Serine/threonine-protein kinase Pim-3 is an enzyme encoded by the PIM3. It prevents apoptosis. It contribute to tumorigenesis through the delivery of survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X(L), by regulation of cell cycle progression, protein synthesis and by regulation of MYC transcriptional activity.

Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 3 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecule, respectively. Report covers products from therapy areas Oncology and Undisclosed which include indications Hematological Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Myelofibrosis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Bladder Cancer, Follicular Lymphoma, Marginal Zone B-cell Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Myeloproliferative Disorders, Non-Small Cell Lung Carcinoma, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Unspecified, Unspecified Cancer and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

The latest report SerineThreonine Protein Kinase Pim 3 – Drugs In Development, 2022, outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1)
- The report reviews Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1)) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

❖ レポートの目次 ❖

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) – Overview
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) – Companies Involved in Therapeutics Development
Incyte Corp
Inflection Biosciences Ltd
NewBay Medical Technology Co Ltd
Novartis AG
Onconova Therapeutics Inc
Shengke Pharmaceuticals (Jiangsu) Ltd
Sumitomo Dainippon Pharma Oncology, Inc
X-37 LLC
Yakult Honsha Co Ltd
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) – Drug Profiles
ETH-155008 – Drug Profile
Product Description
Mechanism Of Action
History of Events
GDC-0570 – Drug Profile
Product Description
Mechanism Of Action
History of Events
IBL-100 – Drug Profile
Product Description
Mechanism Of Action
History of Events
INCB-53914 – Drug Profile
Product Description
Mechanism Of Action
History of Events
LGB-321 – Drug Profile
Product Description
Mechanism Of Action
ON-108110 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit PIM1, PIM2 and PIM3 for Solid Tumors and Hematological Tumors – Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit PIM1 and PIM3 for Hematological Cancers – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit PIM3 for Unspecified Cancer – Drug Profile
Product Description
Mechanism Of Action
TP-3654 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) – Dormant Products
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) – Discontinued Products
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) – Product Development Milestones
Featured News & Press Releases
Apr 10, 2021: Sumitomo Dainippon Pharma Oncology presents on TP-3654 at AACR Virtual Annual Meeting I 2021
May 29, 2020: Tolero Pharmaceuticals presents findings from first clinical studies evaluating investigational agent TP-3654 in patients with advanced solid tumors at ASCO Virtual Annual Meeting 2020
Apr 06, 2020: Boston Biomedical announces first patient dosed in phase 1 study of investigational agent TP-3654 in patients with myelofibrosis
May 14, 2019: Tolero Pharmaceuticals announces first patient dosed in phase 1 study of investigational agent TP-3654 in patients with advanced solid tumors
Oct 23, 2017: Tolero Pharma To Present Preclinical Data Supporting Development of Cancer Drug Candidate TP-3654 for Myc-dependent Triple Negative Breast Cancer
Oct 05, 2017: Tolero Pharma to Deliver Keynote Presentations at 9th International Conference on Leukemia and Hematologic Oncology
Jun 30, 2014: Tolero’s PIM Kinase Inhibitor Demonstrates Promising Activity in Preclinical Models of Urothelial Carcinoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Incyte Corp, 2022
Pipeline by Inflection Biosciences Ltd, 2022
Pipeline by NewBay Medical Technology Co Ltd, 2022
Pipeline by Novartis AG, 2022
Pipeline by Onconova Therapeutics Inc, 2022
Pipeline by Shengke Pharmaceuticals (Jiangsu) Ltd, 2022
Pipeline by Sumitomo Dainippon Pharma Oncology, Inc, 2022
Pipeline by X-37 LLC, 2022
Pipeline by Yakult Honsha Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ セリン/スレオニンプロテインキナーゼPim3(Pim3がん遺伝子)の世界市場2022(Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆